Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05172089
Other study ID # STUDY23050116
Secondary ID 3R01DK125835-02S
Status Recruiting
Phase
First received
Last updated
Start date April 2, 2024
Est. completion date June 27, 2029

Study information

Verified date April 2024
Source University of Pittsburgh
Contact Bryce Hockman, CCRP
Phone 317 278 2715
Email bbhockma@iu.edu
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Diabetic foot ulcers (DFU) are one of the most common reasons for hospitalization of diabetic patients and frequently results in amputation of lower limbs. Of the one million people who undergo non-traumatic leg amputations annually worldwide, 75% are performed on people who have type 2 diabetes (T2DM). The risk of death at 10 years for a diabetic with DFU is twice as high as the risk for a patient without a DFU. The rate of amputation in patients with DFU is 38.4%4. Infection is a common (>50%) complication of DFU. Emerging evidence underscores the significant risk that biofilm infection poses to the non-healing DFU. Biofilms are estimated to account for 60% of chronic wound infections. In the biofilm form, bacteria are in a dormant metabolic state. Thus, standard clinical techniques like the colony forming unit (CFU) assay to detect infection may not detect biofilm infection. Thus, biofilm infection may be viewed as a silent maleficent threat in wound care.


Description:

In the current standard of care (SoC), wound closure is defined (FDA) by wound area re-epithelialization without drainage. The investigators' pre-clinical large animal work demonstrates that wounds with a history of biofilm infection may meet above criteria but the repaired wound-site skin is deficient in barrier function. This has led to the concept of functional wound closure wherein the current clinical definition of wound closure is supplemented with a functional parameter - restoration of skin barrier function as measured by low trans-epidermal water loss (TEWL). This study rests on DFU-patient based findings from a NIDDK-DIACOMP funded pilot study (Sen/Gurtner) showing that closed DFU with deficient barrier function are more likely to recur. Biofilm infection as assessed through scanning electron microscopy and wheat germ aggluttin assay performed on debrided tissue causes faulty re-epithelialization, compromising skin barrier function at the closed wound site. Such defects are caused by biofilm-inducible miRs which silence junctional proteins necessary for skin barrier function. The IRB protocol associated with this study, rests on our novel patient-based observation that in wound-edge tissue catenin delta1/p120 catenin (CTNND1) is suppressed as measured through immunohistochemistry. CTNND1 is an essential regulator of E-cadherin stability which is regarded as a master organizer in epithelial phenotype and plays a critical role in maintaining the barrier integrity of skin. Our prior study identified miR-9 is a biofilm induced microRNA that targets adherens junction protein E-cadherin. We propose that miR-9 can target CTNND1 (Aim 1). The validation of miR targeting will be performed quantitative real time PCR, Western blot analyses, Argonaute 2 pull down assay and on bead assay. Thus, this proposal, fully based on the study of DFU patients, seeks to conduct a fully powered clinical study testing whether DFU with a history of biofilm infection closes with deficient barrier function (Aim 2). Aim 3 tests whether such functionally deficient wound closure, manifested as high TEWL, is associated with greater wound recurrence. Per FDA, the significance of association studies is heightened by support of a well-founded biological rationale provided by mechanistic studies22. This proposal rests on such mechanisms that have been reported by us in pre-clinical large animal studies18-20. The primary parent study will address molecular mechanisms implicated in biofilm-induced loss of skin epithelial barrier integrity in DFU patients.


Recruitment information / eligibility

Status Recruiting
Enrollment 405
Est. completion date June 27, 2029
Est. primary completion date June 27, 2027
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Male or Female, Age = 18 - Willing to comply with protocol instructions, including all study visits and study activities. - Patient with an open Diabetic Foot Ulcer - Adequate arterial blood flow as evidenced by at least one of the following (for wounds below the knee): - TcOM >30 mmHg - Ankle-brachial index =0.7-1.20 - Toe pressure > 30 mmHg - TBI > 0.6 mmHg Exclusion Criteria: - Individuals who are deemed unable to understand the procedures, risks, and benefits of the study. - Wounds closed or to be surgically closed by flap or graft coverage - Subjects with marked immunodeficiency (HIV/AIDS, or on immunosuppressive medications. - TcOM < 30mmHg - Diabetics with a hemoglobin A1c > 12 within 3 months prior to enrollment - Subject with autoimmune connective tissue disease - Ulcer size and location that does not allow the TEWL measurement per SOP - Pregnant women - Prisoners - Unable to comply with study procedures and/or complete study visits

Study Design


Intervention

Procedure:
Observation of wound infection and time to wound closure
Observational: collecting data on length of time to wound closure
Device:
Pericam PSI-NR Laser Speckle imaging
non-invasive non-contact device providing two-dimensional imaging of peripheral tissue blood perfusion. Reduced blood flow may lead to insufficient tissue oxygenation and, thus, assessment of peripheral vascular function has several clinical applications.

Locations

Country Name City State
United States UPMC Wound Healing Services at UPMC Passavant Cranberry Township Pennsylvania
United States University of Arizona Tucson Arizona

Sponsors (3)

Lead Sponsor Collaborator
University of Pittsburgh National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), University of Arizona

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Aim 1 Determine how biofilm-induced DFU tissue microRNA's disrupt barrier function of the repairing DFU 16 weeks
Primary Aim 2 Test the incidence of wound biofilm infection at initial visit and test its association with deficient skin barrier function at the closed DFU-site 16 weeks
Primary Aim 3 Test whether closed DFU with deficient barrier function is associated with higher rate of recidivism 12 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT06154915 - Immune Cells in Diabetic Chronic Foot Ulcers
Completed NCT04624516 - Effect of Self-foot Exercise on the Incidence of Plantar Foot Diabetic Ulcer Recurrence N/A
Not yet recruiting NCT06278935 - Lifestyle Tailored Offloading for Diabetic Foot Ulcers N/A
Completed NCT02373592 - Implementation of Foot Thermometry and SMS and Voice Messaging to Prevent Diabetic Foot Ulcer N/A
Active, not recruiting NCT01903044 - Safety and Efficacy of Autologous Bone Marrow Stem Cells for Lower Extremity Ischemia Treating Phase 1/Phase 2
Completed NCT02092870 - Adipose Derived Regenerative Cellular Therapy of Chronic Wounds Phase 2
Completed NCT01212120 - The Foot in Your Nose Study: Links Between Nasal Staphylococcus Aureus Colonies and Diabetic Foot Lesion Infections N/A
Completed NCT00402727 - Comparison of Sequential IV/PO Moxifloxacin With IV Piperacillin/Tazobactam Followed by PO Amoxicillin/Clavulanic Acid in Patients With a Complicated Skin and Skin Structure Infection Phase 3
Recruiting NCT04085705 - The Prevalence of Contact Allergies for Wound Dressings In Patients With Diabetic Foot Ulcers (PAID Study)
Completed NCT04054804 - Digital Foot Check by Using the D-Foot, a New Software
Completed NCT04480801 - The Effect of Thermal Evaluation in Prevention of Diabetic Foot Ulcer N/A
Not yet recruiting NCT04537676 - Patient Empowerment Study
Recruiting NCT04564443 - A Unique Micro Water Jet Technology Device Versus Standard Debridement in the Treatment of Diabetic Foot N/A
Recruiting NCT05974592 - The Effect of Nurse-Led Diabetic Foot Self-Management Training Program N/A
Not yet recruiting NCT04630795 - ViscoTurf - Preventing Secondary Diabetic Foot Ulceration.
Not yet recruiting NCT05431660 - Diabetic Foot School and Biomechanics N/A
Completed NCT05101473 - Exercise Therapy for People With a Diabetic Foot Ulcer - a Feasibility Study N/A
Completed NCT05123157 - Pattern and Type of Amputation and Mortality Rate Associated With Diabetic Foot in Jeddah, Saudi Arabia: A Retrospective Cohort Study
Enrolling by invitation NCT05043636 - Diabetic Neuropathy Screening Study 1.1 + Substudy 1.2-1.3-1.4
Completed NCT03254095 - Predictors of Skin Temperature, Plantar Pressure and Ulceration in Diabetic Foot Patients.